Möchten Sie immer auf dem neuesten Stand bleiben?

Oslo, Norway, September 12th, 2016: Photocure ASA announced today that data from the OPTIC III study:  Optimized photodynamic diagnosis for transurethral resection of the bladder tumor (TURBT) in...

Update on management shareholdings and exercise of employee share options in Photocure ASA ("the Company"). Oslo, Norway, 6 September 2016  1.  Participants in the Photocure's share option...

Oslo, Norway, August 29, 2016 -- Photocure ASA hosted on August 25 an educational event in New York aimed at institutional investors and analysts, which focused on the treatment of bladder cancer....

Oslo, Norway, August 24, 2016: Photocure ASA (OSE: PHO), announces that its partner and exclusive distributor, Juno Pharmaceuticals Pty Ltd, have received marketing authorization approval (MAA) for...

Oslo, Norway, 23 August 2016: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a sales revenue growth of 18 % to...

Photocure will present its second quarter report on Tuesday 23 August 2016 at Hotel Continental, Oslo, Norway. Additionally, Dr. Daneshmand will provide an update on Hexvix/Cysview following the...

New Cysview kit has an improved design providing healthcare professionals with an improved, simplified, and easy-to-use product. Oslo, Norway, August 11, 2016: Photocure ASA (OSE: PHO), announces...

Oslo, Norway, August 2, 2016 -- Photocure ASA announced today a new systematic review and meta-analysis on the impact of Blue Light Cystoscopy (BLC) with Hexvix® (Hexaminolevulinate) - versus White...

Oslo, Norway, 6 July 2016: Photocure ASA will present its second quarter report on Tuesday 23 August 2016 at Hotel Continental, Norway, and is proud to announce Dr. Sia Daneshmand as keynote...

Oslo, Norway, 26 May 2016: Photocure ASA announces today that its Chief Operating Officer, Kathleen Deardorff, has resigned effective 1 June 2016 to pursue other career opportunities. Ms Deardorff...